EBOS Group (NZSE:EBO) Earnings Put Valuation Back In Focus

EBOS Group earnings put fresh focus on the stock

EBOS Group (NZSE:EBO) has drawn fresh attention after releasing full year 2026 results today, reporting A$13,486.68m in sales and A$225.19m in net income from continuing operations.

See our latest analysis for EBOS Group.

The earnings release appears to have reset sentiment around EBOS Group, with the share price at NZ$23.55 after a 16.01% 90 day share price return. However, the 1 year total shareholder return has declined 38.77%, suggesting recent momentum is rebuilding after a weaker period.

If you are weighing this earnings reaction and want to see what else is moving, it can help to scan other healthcare related ideas through 131 healthcare AI stocks

EBOS Group now combines a large, diversified healthcare and animal care business with a share price that has bounced in recent months but is still well down over the year. This raises the question of whether this renewed optimism is already fully reflected in the valuation.

Most Popular Narrative: 22.0% Undervalued

On the most followed narrative, EBOS Group screens as undervalued, with a fair value of NZ$30.13 against the last close of NZ$23.55. That gap is built on detailed views of future earnings, margins and capital efficiency.

EBOS' major multi-year distribution center renewal program is concluding in FY '26, creating a step-change in logistics capacity, automation, and service efficiency. This is set to significantly lower operating costs and improve margins from FY '27 onwards as capital expenditures normalize and productivity benefits ramp up. (Likely impact: net margins, future earnings growth)

Read the complete narrative.

This narrative leans heavily on what happens after the current investment phase. Revenue growth, tighter margins and a higher earnings base are all baked into the story. It may be useful to examine which specific profit and valuation assumptions would need to hold for that NZ$30.13 fair value to be supported.

Result: Fair Value of NZ$30.13 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, EBOS Group still faces pressure if wholesale pharmacy margins stay weak or if higher distribution center and financing costs continue to weigh on profitability for longer than expected.

Find out about the key risks to this EBOS Group narrative.

Another view on EBOS Group valuation

While the narrative fair value suggests EBOS Group is undervalued at NZ$23.55 versus NZ$30.13, the P/E picture is less clear. The current P/E of 17.6x is higher than the 16.4x fair ratio and the 9.2x peer average, yet below the 20.3x global healthcare level. That mix points to both potential upside and valuation risk. Which reference point do you trust most for your own framework?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed tone around EBOS Group in this earnings reaction, it makes sense to move quickly and test the numbers against your own approach. To see how that balance of concerns and optimism looks in detail, start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond EBOS Group?

If you want to put EBOS Group in context and avoid missing other opportunities, it helps to compare it with a wider set of potential stocks.

• Spot potential bargains early by scanning companies that screen as attractively priced with solid fundamentals through 261 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies that offer higher yields and resilient payouts using the 434 dividend fortresses.
• Reduce portfolio stress by checking companies that currently carry lower overall risk scores via the 288 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com